Adverse effects of systemic advanced melanoma therapies—do BRAF/MEK inhibitors increase the incidence of mesenteric panniculitis?

1

Melanoma accounts for 1% of skin cancers but causes 80% of skin cancer deaths, highlighting its severity.
2

Recent therapies for advanced melanoma include BRAF/MEK inhibitors and immune checkpoint inhibitors, improving survival rates.
3

BRAF/MEK inhibitors are associated with adverse effects, including a rare increase in mesenteric panniculitis.
4

Mesenteric panniculitis is a benign disorder characterized by chronic inflammation of mesenteric adipose tissue.
5

The study analyzed 490 melanoma patients to investigate the incidence of mesenteric panniculitis following advanced therapies.

European Radiology

by Marcel Alexander Drews, Alexander Baumgarten, Sebastian Zensen, Marcel Opitz, Denise Bos, Lisa Zimmer, Selma Ugurel, Johannes Haubold, Dirk Schadendorf, Elisabeth Livingstone, Benedikt M. Schaarschmidt
May 1, 2025

1